We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock
VYNT

Delisted

VYNT was delisted on the 12th of May, 2023.

Back to rankings

21 hedge funds and large institutions have $1.47M invested in Vyant Bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

9% less funds holding

Funds holding: 23 → 21 (-2)

42% less capital invested

Capital invested by funds: $2.54M → $1.47M (-$1.07M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$22.5K
2
UBS Group
UBS Group
Switzerland
+$7.15K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.08K
4
State Street
State Street
Massachusetts
+$2.81K
5
Renaissance Technologies
Renaissance Technologies
New York
+$781

Top Sellers

Rank Fund Capital Flow
1
Cerity Partners
Cerity Partners
New York
-$171K
2
BlackRock
BlackRock
New York
-$67.7K
3
Citadel Advisors
Citadel Advisors
Florida
-$50K
4
TRCT
Tower Research Capital (TRC)
New York
-$8K
5
TWMP
Taylor Wealth Management Partners
Massachusetts
-$3K

VYNT Hedge Fund Activity: Q2 2022 in Review

21 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2022, worth a combined $1.47M — down 42% from $2.54M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of VYNT and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 6 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $22.5K. The largest seller was Cerity Partners, exiting entirely with an estimated $171K sold.

  • 21 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2022, down from 23 in Q1 2022.
  • Funds reported $1.47M of Vyant Bio, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
  • 2 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of -2 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q2 2022 was Virtu Financial, an estimated $22.5K added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q2 2022 was Cerity Partners, an estimated $171K sold.

Based on aggregated 13F filings for Q2 2022.